"Hypolipidemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
| Descriptor ID |
D000960
|
| MeSH Number(s) |
D27.505.519.186.071 D27.505.954.557.500
|
| Concept/Terms |
Hypolipidemic Agents- Hypolipidemic Agents
- Agents, Hypolipidemic
- Antihyperlipidemics
- Hypolipidemic Drugs
- Drugs, Hypolipidemic
- Antilipemic Drugs
- Drugs, Antilipemic
- Antilipemics
- Antihyperlipemics
- Antilipemic Agents
- Agents, Antilipemic
|
Below are MeSH descriptors whose meaning is more general than "Hypolipidemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypolipidemic Agents".
This graph shows the total number of publications written about "Hypolipidemic Agents" by people in this website by year, and whether "Hypolipidemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 3 | 3 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 0 | 2 |
| 2016 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypolipidemic Agents" by people in Profiles.
-
Pathogenic Role of PPARa Downregulation in Corneal Nerve Degeneration and Impaired Corneal Sensitivity in Diabetes. Diabetes. 2020 06; 69(6):1279-1291.
-
Autophagy augmentation alleviates cigarette smoke-induced CFTR-dysfunction, ceramide-accumulation and COPD-emphysema pathogenesis. Free Radic Biol Med. 2019 02 01; 131:81-97.
-
Lipids and Women's Health: Recent Updates and Implications for Practice. J Womens Health (Larchmt). 2019 06; 28(6):752-760.
-
Therapeutic Effects of PPARa Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2017 10 01; 58(12):5065-5075.
-
JCL roundtable: Managing lipid disorders in young women. J Clin Lipidol. 2016 Sep-Oct; 10(5):1058-66.
-
Fenofibrate Reverses Palmitate Induced Impairment in Glucose Uptake in Skeletal Muscle Cells by Preventing Cytosolic Ceramide Accumulation. Cell Physiol Biochem. 2015; 37(4):1315-28.
-
PPARa regulates mobilization and homing of endothelial progenitor cells through the HIF-1a/SDF-1 pathway. Invest Ophthalmol Vis Sci. 2014 May 20; 55(6):3820-32.
-
Protective and antioxidant effects of PPARa in the ischemic retina. Invest Ophthalmol Vis Sci. 2014 May 13; 55(7):4568-76.
-
Medication use following bariatric surgery: factors associated with early discontinuation. Obes Surg. 2014 May; 24(5):696-704.
-
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation. 2011 Oct 25; 124(17):1811-8.